Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324 | Completed Phase 4 FDA Drug

• 1 other identifier: COVID-19 and Immunodeficiency
• Study Type: interventional
• Target: 82
• Locations: 2 countries
• Sites: 2

Brief Summary

AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Conditions

Covid19

Keywords

AIDS; HIV; HBV; HCV; Stroke; Metabolic dissorder; Stress

Outcome Measures

Primary Outcomes (1)

• Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1)

  COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 * One case of Covid-19 infection with no severe change in a patient with HBeAg (+). * A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated).

  - 18 months

Secondary Outcomes (1)

• Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2)

  - 18 months

Study Arms (2)

AntiCov-220

EXPERIMENTAL

Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes.

Drug: AntiCov-220

AntiCov-220 (Placebo)

EXPERIMENTAL

Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (placebo) for various therapeutic purposes.

Drug: AntiCov-220 (placebo)

Interventions

AntiCov-220 DRUG

The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.

Also known as: 1a

AntiCov-220

AntiCov-220 (placebo) DRUG

The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.

Also known as: 1b

AntiCov-220 (Placebo)

Eligibility Criteria

• Age: 16 Years - 82 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients with underlying medical conditions who have been taking medications for these conditions.
• Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
• The cancer patients are stable.
• Patients with congenital or acquired immunodeficiency.

You may not qualify if:

• Unstable cancer patients.

Sponsors & Collaborators

• Nguyen Thi Trieu, MD: lead

Study Sites (2)

Saigon Biopharma LLC

Wilmington, Delaware, 19801-6601, United States

Location

Saigon Biopharma Company Limited

Ho Chi Minh City, 700000, Vietnam

Location

MeSH Terms

Conditions

COVID-19; Acquired Immunodeficiency Syndrome; Stroke

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; HIV Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Tran Minh Cam Tu, Dr.

  Saigon Biopharma Company Limited

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDIV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: CEO

Study Record Dates

• First Submitted: September 8, 2021
• First Posted: September 14, 2021
• Study Start: February 20, 2020
• Primary Completion: April 20, 2022
• Study Completion: April 27, 2022
• Last Updated: September 11, 2025

Record last verified: 2025-09

Locations

US (1); VN (1)